Novo Nordisk Receives Positive EMA Opinion to Update Ozempic Label With Risk Reduction of Kidney Disease-Related Events

MT Newswires Live

Dec 14, 2024

Novo Nordisk (NVO) said Thursday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for an update of the Ozempic, or semaglutide, label to include risk reduction of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.

In the FLOW trial, which assessed how effectively Ozempic reduces the risk of chronic kidney disease-related events, semaglutide 1.0 milligram showed a "statistically significant and superior" 24% risk reduction in kidney disease progression, and cardiovascular and kidney death, versus placebo, the company said.

Additionally, Novo Nordisk said it has filed for a label expansion in the US, with a decision expected in H1 2025.

Shares of Novo Nordisk were down 2.4% in recent Friday trading.

Price: 105.98, Change: -2.63, Percent Change: -2.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491596372"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491596372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491596372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 00:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491596372","market":"us","top_or_hot":-1,"title":"Novo Nordisk Receives Positive EMA Opinion to Update Ozempic Label With Risk Reduction of Kidney Disease-Related Events","media":"MT Newswires Live","content":"<html><body><p> Novo Nordisk (NVO) said Thursday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for an update of the Ozempic, or semaglutide, label to include risk reduction of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.</p><p>In the FLOW trial, which assessed how effectively Ozempic reduces the risk of chronic kidney disease-related events, semaglutide 1.0 milligram showed a \"statistically significant and superior\" 24% risk reduction in kidney disease progression, and cardiovascular and kidney death, versus placebo, the company said.</p><p>Additionally, Novo Nordisk said it has filed for a label expansion in the US, with a decision expected in H1 2025.</p><p>Shares of Novo Nordisk were down 2.4% in recent Friday trading.</p><p>Price: 105.98, Change: -2.63, Percent Change: -2.42</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Receives Positive EMA Opinion to Update Ozempic Label With Risk Reduction of Kidney Disease-Related Events</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Receives Positive EMA Opinion to Update Ozempic Label With Risk Reduction of Kidney Disease-Related Events\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-14 00:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Novo Nordisk (NVO) said Thursday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for an update of the Ozempic, or semaglutide, label to include risk reduction of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.</p><p>In the FLOW trial, which assessed how effectively Ozempic reduces the risk of chronic kidney disease-related events, semaglutide 1.0 milligram showed a \"statistically significant and superior\" 24% risk reduction in kidney disease progression, and cardiovascular and kidney death, versus placebo, the company said.</p><p>Additionally, Novo Nordisk said it has filed for a label expansion in the US, with a decision expected in H1 2025.</p><p>Shares of Novo Nordisk were down 2.4% in recent Friday trading.</p><p>Price: 105.98, Change: -2.63, Percent Change: -2.42</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7104","symbol_name":"黄金","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491596372","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491596372","pubTimestamp":1734105989,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  said Thursday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for an update of the Ozempic, or semaglutide, label to include risk reduction of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.In the FLOW trial, which assessed how effectively Ozempic reduces the risk of chronic kidney disease-related events, semaglutide 1.0 milligram showed a \"statistically significant and superior\" 24% risk reduction in kidney disease progression, and cardiovascular and kidney death, versus placebo, the company said.Additionally, Novo Nordisk said it has filed for a label expansion in the US, with a decision expected in H1 2025.Shares of Novo Nordisk were down 2.4% in recent Friday trading.Price: 105.98, Change: -2.63, Percent Change: -2.42","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7104":"黄金","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","NVO.AU":"NOVO RESOURCES CORP-CDI","BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德"},"translate_title":"诺和诺德获得EMA积极意见，更新Ozempic标签，降低肾脏疾病相关事件的风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO.AU":1,"NVO":1},"content_text":"Novo Nordisk (NVO) said Thursday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for an update of the Ozempic, or semaglutide, label to include risk reduction of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.In the FLOW trial, which assessed how effectively Ozempic reduces the risk of chronic kidney disease-related events, semaglutide 1.0 milligram showed a \"statistically significant and superior\" 24% risk reduction in kidney disease progression, and cardiovascular and kidney death, versus placebo, the company said.Additionally, Novo Nordisk said it has filed for a label expansion in the US, with a decision expected in H1 2025.Shares of Novo Nordisk were down 2.4% in recent Friday trading.Price: 105.98, Change: -2.63, Percent Change: -2.42","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}